QTTB Stock Summary and Trading Ideas (Q32 Bio | NASDAQ:QTTB)

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio trades on the NASDAQ stock market under the symbol QTTB.

As of December 13, 2024, QTTB stock price declined to $3.70 with 1,822,955 million shares trading.

QTTB has a beta of 2.40, meaning it tends to be more sensitive to market movements. QTTB has a correlation of 0.02 to the broad based SPY ETF.

QTTB has a market cap of $45.07 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that QTTB belongs to (by Net Assets): VTI, VXF, VTWO, IWM, IWN.

QTTB support price is $3.88 and resistance is $4.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTTB shares will trade within this expected range on the day.